Centre National De La Recherche Scientifique

Universitè De Montpellier

Bio-rad Europe Gmbh

Bio-rad Pasteur

Chu Montpellier

Chu Monpellier

Skillcell

Bio-rad Innovations

Alcediag

Franck Molina

Pierre Martineau

Dinah Weissmann

Alain Thierry

Claude Granier

Nicolas Salvetat

Jean-François Pujol

Siem Van Der Laan

Laurence Molina

Randa Siala

Eric Renard

Karine Piot

Claire Lamoure

Alexis Courbet

Francisco Santos Schneider

The present invention is directed to a method for the preparation of a non-living micro/nanoscale biosynthetic device capable of giving an information of a state of a system to analyse. Preferably, said device is used as an assay diagnostic, or to predict the risk, of a disease, or for the classification of mammal, preferably human pathologies. The invention also relates to a method for the identification and/or the quantification of a compound in a sample. Finally the present invention includes a kit comprising the biosynthetic device obtained by the method of the present invention.

Method for the preparation of biosynthetic device and their uses in diagnostics

The present invention is directed to an in vitro method of detecting cell free nucleic acids, preferably cell free DNA (cfDNA) in a body fluid sample from an individual or a patient, wherein the method comprises the step of accurately and sensitively determining the concentration of cell free nucleic acid in the sample and/or determining the concentration or amount of said cell free nucleic acid of a size range and/or the index of integrity or size fraction ratio (SFR) of said cell free nucleic acid and/or the determination of the presence of genetic polymorphisms (such as known Single Nucleotide Polymorphisms (SNPs) or mutations). The invention encompasses also a method to discriminate body fluid individuals where cfDNA are highly released by comparing the size profile obtained for at least one of three size ranges of cfDNA. The invention also encompasses a method for analysing cell free nucleic acids in individuals for the diagnosis, prognosis or for assessing the evolution of a physiological state, such as the progression of a tumor or metastatic cancer, for monitoring the efficacy of a cancer treatment in a patient or for theragnostic purposes implementing the analysis of these biomarkers.

Analytical methods for cell free nucleic acids and applications

The present invention concerns a method for the in vitro detection of an increased risk of diabetic nephropathy in a subject suffering from diabetes and being normoalbuminuric. Another aspect of the invention pertains to a method for the in vitro identification of a marker for prediction of diabetic nephropathy. Finally, the invention concerns a kit comprising means for detecting at least two proteins selected from the group consisting of heparan sulfate proteoglycan core protein or fragments thereof, carbonic anhydrase 1, prothrombin or fragments thereof, tetranectin, CD59 glycoprotein, plasma serine protease inhibitor, mannan-binding lectin serine protease 2 or isoforms thereof, antithrombin-III, alpha-1-antitrypsin, collagen alpha-1(I) chain, alpha-enolase, histone H2B type 1-O, glutaminyl-peptide cyclotransferase, protein AMBP and zinc-alpha-2-glycoprotein.

Early prediction markers of diabetic nephropathy

The present invention is directed to an in vitro method of detecting cell free nucleic acids, preferably cell free DNA (cfDNA) in a body fluid sample from an individual or a patient, wherein the method comprises the step of accurately and sensitively determining the concentration of cell free nucleic acid in the sample and/or determining the concentration or amount of said cell free nucleic acid of a size range and/or the index of integrity or size fraction ratio (SFR) of said cell free nucleic acid and/or the determination of the presence of genetic polymorphisms (such as known Single Nucleotide Polymorphisms (SNPs) or mutations). The invention encompasses also a method to discriminate body fluid individuals where cfDNA are highly released by comparing the size profile obtained for at least one of three size ranges of cfDNA. The invention also encompasses a method for analyzing cell nucleic acids in individuals for the diagnosis, prognosis or for assessing the evolution of a physiological state, such as the progression of a tumor or metastatic cancer, for monitoring the efficacy of a cancer treatment in a patient or for theragnostic purposes implementing the analysis of these biomarkers.

In order to estimate the size of an initial population of nucleic acids in a sample of interest, in particular by PCR, the following steps are performed:

Method, an installation, and a computer program for estimating the initial size of a population of nucleic acids, in particular by PCR

Growing community of inventors

Les Matelles, France

Franck Molina